Drug Trial Radar · NCT05871970
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
38
Planned (sponsor's estimate)
Start
Oct 18, 2023
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Protara TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6 months to less than 2 years. The Phase 2b is an expansion study in which enrollment of participants will be initiated after safety has been established in each cohort during the Phase 2a safety lead-in study. Each participant will receive up to 4 injections of TARA-002 spaced approximately 6 weeks apart.
Conditions
- Lymphatic Malformation
Interventions
TARA-002Biological
All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with clinical success after one treatment cycle of TARA-002Time frame: 8 weeks after the last injection
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama · Recruiting
Arkansas Children's Hospital/UAMS
Little Rock, Arkansas · Recruiting
Children's Hospital of Colorado
Aurora, Colorado · Recruiting
Children's National Medical Center: Children's Research Institute
Washington D.C., District of Columbia · Recruiting
Nemours Children's Clinic - Jacksonville
Jacksonville, Florida · Recruiting
Mount Sinai Hospital
New York, New York · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Withdrawn
Oregon Health & Science University
Portland, Oregon · Recruiting
Children's Hospital of Philadelphia: Comprehensive Vascular Anomalies Program
Philadelphia, Pennsylvania · Withdrawn
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Children's Hospital of the King's Daughters
Norfolk, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.